A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 500 participants.
Also called NCT07776509
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 500 participants
- Sponsor
- Registry
-
NCT07776509 -
2025-523295-23-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Brazil, Canada, China, Denmark, Israel, Japan, Sweden, Türkiye, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07776509. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-24 (actual); primary completion 2028-08-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Acronym
- SELENE 3
- Condition
- Obesity or Overweight
- Condition
- Weight-Related Comorbidity
- Condition
- With/Without Diabetes Mellitus, Type 2
- Intervention (Drug)
- Lenbelintide
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07776509- Content hash
0e4ea31d1532f8d8476b8b827e97b92159e759a238547a50cabc9aa6d1ddc399